WHAT IS CLAIMED IS:

1. A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

Ar is phenyl, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, or imidazolyl; or oxides thereof when Ar is a heteroaryl;

Y is $-COOR^4$, $-C_{1-6}alkyl(C_{1-4}alkyl)_n-COOR^4$, $-C_{3-4}cycloalkyl(C_{1-4}alkyl)_m-COOR^4$, wherein the $-C_{1-6}alkyl$ and the $C_{3-4}cycloalkyl$ is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the $(C_{1-4}alkyl)$ substituents are optionally linked to form a $C_{3-4}cycloalkyl$; wherein n is 0, 1, 2, 3 or 4, m is 0, 1 or 2;

R and R4 are each independently selected from H and $-C_{1-6}alkyl$;

R^1 is H, or $-C_{1-6}alkyl$, $-C_{3-6}cycloalkyl$, $-C_{1-6}alkoxy$, $-C_{2-6}alkenyl$, $-C_{3-6}alkynyl$, heteroaryl, or heterocycle group, optionally substituted with 1-3 independent $haloC_{1-6}alkyl$, $-C_{1-6}alkyl$, $-C_{1-6}alkoxy$, OH, amino, $-(C_{0-6}alkyl)-SO_p-(C_{1-6}alkyl)$, nitro, CN, $=N-O-C_{1-6}alkyl$, $-O-N=C_{1-6}alkyl$, or halogen substituents, wherein p is 0, 1 or 2, or R^1 is $C_{3-6}cycloalkyl$ substituted with phenyl;

R^2 is H, halogen,-CN, $-NO_2$, $-C_{1-6}alkyl$, $-C_{3-6}cycloalkyl$, $-O-C_{3-6}cycloalkyl$, $O-C_{1-6}alkyl$, $O-C_{3-6}cycloalkyl-C_{1-6}alkyl(C_{3-6}cycloalkyl)(C_{3-6}cycloalkyl)$, $-C_{1-6}alkoxy$, phenyl, heteroaryl, heterocycle, amino, $-C(O)-C_{1-6}alkyl$, $-C(O)-O-C_{1-6}alkyl$, $-C_{1-6}alkyl(=N-OH)$, $-C(N=NOH)C_{1-6}alkyl$, $-C_{0-6}alkyl(oxy)C_{1-6}alkyl$-phenyl, $-SO_kNH(C_{0-6}alkyl)$, or $-(C_{0-6}alkyl)-SO_k-(C_{1-6}alkyl)$, wherein the phenyl, heteroaryl or heterocycle is optionally substituted with halogen, $-C_{1-6}alkyl$, $-C_{1-6}alkoxy$, hydroxy, amino, or

-C(O)-O-C_{1-6}alkyl, and wherein the alkyl or cycloalkyl is optionally substituted with 1-6 independently selected halogens or –OH, and wherein k is 0, 1, or 2;

R^3 is selected from H, halogen, CN, -C_{1-6}alkyl, -C_{3-6}cycloalkyl, nitro, -C(O)-C_{1-6}alkyl, -C(O)-O-C_{0-6}alkyl, -$SO_{n'}NH(C_{0-6}alkyl)$, or -$(C_{0-6}alkyl)$-$SO_{n'}$-(C_{1-6}alkyl), O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl, wherein n' is 0, 1, or 2 and wherein the alkyl and cycloalkyl is optionally substituted with 1-6 independently selected halogen or OH.

2. A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

Ar is phenyl, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, or imidazolyl; or oxides thereof when Ar is a heteroaryl;

Y is –COOH, -C_{1-6}alkyl$(C_{1-4}alkyl)_n$-COOH, -C_{3-4}cycloalkyl$(C_{1-4}alkyl)_m$-COOH, wherein the -C_{1-6}alkyl and the C_{3-4}cycloalkyl is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the (C_{1-4}alkyl) substituents are optionally linked to form a C_{3-4}cycloalkyl ; wherein n is 0, 1, 2, 3 or 4, m is 0, 1 or 2;

R is H or –C_{1-6}alkyl;

R^1 is H, or –C_{1-6}alkyl, –C_{3-6}cycloalkyl, –C_{1-6}alkoxy, –C_{2-6}alkenyl, –C_{3-6}alkynyl, heteroaryl, or heterocycle group, optionally substituted with 1-3 independent haloC_{1-6}alkyl, -C_{1-6}alkyl, –C_{1-6}alkoxy, OH, amino, –$(C_{0-6}alkyl)$–SO_p–(C_{1-6}alkyl), nitro, CN, =N-O-C_{1-6}alkyl, -O-N=C_{1-6}alkyl, or halogen substituents, wherein p is 0, 1 or 2;

R^2 is H, halogen,-CN, -NO_2, –C_{1-6}alkyl, –C_{3-6}cycloalkyl, -O- C_{3-6}cycloalkyl, O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl-C_{1-6}alkyl(C_{3-6}cycloalkyl)(C_{3-6}cycloalkyl), –C_{1-6}alkoxy, phenyl, heteroaryl, heterocycle, amino, –C(O)–C_{1-6}alkyl, –C(O)–O–C_{1-6}alkyl, –C_{1-6}alkyl(=N-OH), -C(N=NOH)C_{1-6}alkyl, –C_{0-6}alkyl(oxy)C_{1-6}alkyl-phenyl, –SO_kNH(C_{0-6}alkyl), or -(C_{0-6}alkyl)–SO_k–(C_{1-6}alkyl), wherein the phenyl, heteroaryl or heterocycle is optionally substituted with halogen, -C_{1-6}alkyl, –C_{1-6}alkoxy, hydroxy, amino, or -C(O)-O-C_{1-6}alkyl, and wherein the alkyl or cycloalkyl is optionally substituted with 1-6 independently selected halogens or –OH, and wherein k is 0, 1, or 2;

R^3 is selected from H, halogen, CN, -C_{1-6}alkyl, -C_{3-6}cycloalkyl, nitro, -C(O)-C_{1-6}alkyl, -C(O)-O-C_{0-6}alkyl, -$SO_{n'}$NH(C_{0-6}alkyl), or -(C_{0-6}alkyl)-$SO_{n'}$-(C_{1-6}alkyl), O-C_{1-6}alkyl, O-C_{3-6}cycloalkyl, wherein n' is 0, 1, or 2 and wherein the alkyl and cycloalkyl is optionally substituted with 1-6 independently selected halogen or OH.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein

Y is -C_{3-4}cycloalkyl(C_{1-4}alkyl)$_m$-COOH, wherein the C_{3-4}cycloalkyl is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the (C_{1-4}alkyl) substituents are optionally linked to form a C_{3-4}cycloalkyl ; wherein n is 0, 1, 2, 3 or 4, m is 0, 1 or 2.

4. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein

Y is cyclopropyl-COOH;

Ar is phenyl.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^1 is –C_{1-6}alkyl optionally substituted with 1-3 independent -C_{1-6}alkyl, –C_{1-6}alkoxy, OH, amino, –(C_{0-6}alkyl)–SO_p–(C_{1-6}alkyl), nitro, CN, =N-O-C_{1-6}alkyl, -O-N=C_{1-6}alkyl, or halogen substituents.

6. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^1 is $-C_{3-6}$cycloalkyl optionally substituted with 1-3 independent $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, OH, amino, $-(C_{0-6}alkyl)-SO_p-(C_{1-6}alkyl)$, nitro, CN, =N-O-$C_{1-6}$alkyl, -O-N=$C_{1-6}$alkyl, or halogen substituents.

7. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R is hydrogen.

8. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen or $-C_{1-3}$alkyl.

9. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^1 is $-C_{3-6}$cycloalkyl optionally substituted with methyl or halo; and

R is hydrogen.

10. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^1 is cyclopropyl optionally substituted with methyl or halo; and

R and R^2 are hydrogen.

11. The compound according to claim 2, or a pharmaceutically acceptable salt, wherein

Ar is pyridyl, pyrimidyl, or oxide thereof.

12. The compound according to claim 11, or a pharmaceutically acceptable salt, wherein

R^1 is $-C_{1-6}$alkyl optionally substituted with 1-3 independent $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, OH, amino, $-(C_{0-6}alkyl)-SO_p-(C_{1-6}alkyl)$, nitro, CN, =N-O-$C_{1-6}$alkyl, -O-N=$C_{1-6}$alkyl, or halogen substituents.

13. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R^1 is $-C_{3-6}$cycloalkyl optionally substituted with 1-3 independent $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, OH, amino, $-(C_{0-6}alkyl)-SO_p-(C_{1-6}alkyl)$, nitro, CN, $=N-O-C_{1-6}$alkyl, $-O-N=C_{1-6}$alkyl, or halogen substituents.

14. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R is hydrogen.

15. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen or .$-C_{1-3}$alkyl or halogen.

16. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R^1 is $-C_{3-6}$cycloalkyl optionally substituted with methyl or halo; and

R is hydrogen.

17. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein

R^1 is cyclopropyl optionally substituted with methyl or halo; and

R and R^2 are hydrogen or halogen;

R^3 is hydrogen or halogen.

18. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein

R and R^3 are hydrogen,;

R^1 is $-C_{3-6}$cycloalkyl optionally substituted with methyl or halo, or $-C_{1-3}$alkyl optionally substituted with 1-3 halo; and

Ar is phenyl.

19. The compound according to claim 18 wherein

R^2 is hydrogen or halo; and
Y is $-CH_3$-C_{3-4}cycloalkyl –COOH or -C_{3-4}cycloalkyl-COOH.

20. The compound according to claim 2, which is
2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}cyclopropanecarboxylic acid;
2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}-2-methylpropanoic acid;
2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-2-methylpropanoic acid;
3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-3-methylbutanoic acid;
{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}(hydroxy)acetic acid;
1-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
2-(cis)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
5-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid;
1-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}cyclopropanecarboxylic acid;
1-cyano-3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-2,2-dimethylcyclopropanecarboxylic acid;
2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-3-fluoro-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;
(cis)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-3-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-bromo-5'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-3-methyl-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-2-methyl-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(cis)-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-3-fluoro-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-carboxylic acid;

2-(trans)-{3'-[3-(morpholin-4-ylcarbonyl)-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[4-oxo-3-({[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]amino}carbonyl)-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[3-({[2-(methylthio)ethyl]amino}carbonyl)-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[3-({[2-(methylsulfonyl)ethyl]amino}carbonyl)-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-(5-{3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]phenyl}thien-2-yl)cyclopropanecarboxylic acid;

2-(trans)-{3'-[3-{[(cyclopropylmethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid;

2-(trans)-{3'-[3-{[(1-cyanocyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}cyclopropanecarboxylic acid; or

3-{3'-[3-[(isopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-1,1'-biphenyl-4-yl}-3-methylbutanoic acid.

21. A compound of claim 1 which is

(+)-(trans)-2-{3-fluoro-3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

1-({3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}methyl)cyclobutanecarboxylic acid;

(trans)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2-methylcyclopropanecarboxylic acid;

(trans)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}cyclopropanecarboxylic acid;

3-methyl-3-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}butanoic acid;

(trans)-2-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}cyclopropanecarboxylic acid;

(trans)-2-{3'-[4-oxo-3-{[(2,2,3,3,3-pentafluoropropyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(trans)-2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-1-fluorocyclopropanecarboxylic acid;

(+)-(trans)-2-{3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(-)-(trans)-2-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(+)-(trans)-ethyl 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylate;

(+)-(trans)-isopropyl 2-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylate;

tert-butyl 3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2,2-dimethylpropanoate;

3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2,2-dimethylpropanoic acid;

3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-3-yl}-2,2-dimethylpropanoic acid;

1-({3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-3-yl}methyl)cyclobutanecarboxylic acid;

3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}-2,2-dimethylpropanoic acid;

1-({3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-2-yl}methyl)cyclobutanecarboxylic acid;

(+)-(trans)-2-{3'-[3-[(*tert*-butylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(+)-(trans)-2-{3'-[3-[(cyclobutylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

3-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}bicyclo[1.1.1]pentane-1-carboxylic acid;

4-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-4-hydroxypentanoic acid;

(trans)-2-{3'-[3-{[(±)-cis-(2-fluorocyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-(+)-biphenyl-4-yl}cyclopropanecarboxylic acid;

(+)-(trans)-2-{3'-[3-{[(dicyclopropylmethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

4-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-2,2-dimethylbutanoic acid;

(+)-(trans)-2-{3'-[3-{[(1-hydroxycyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(+)-(trans)-2-{3'-[4-oxo-3-{[(1-phenylcyclopropyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

4-{3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}-3,3-dimethylbutanoic acid;

(+)-(trans)-2-{3'-[3-{[(1-cyclopropyl-1-methylethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

1-({3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}methyl)cyclobutanecarboxylic acid;

(+)-(trans)-2-{3'-[3-{[(cyclopropylmethyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(-)-(trans)-2-{3-fluoro-3'-[3-{[(1-hydroxycyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

(trans)-2-{3'-[4-oxo-3-{[(±)-2,2,2-trifluoro-1-methylethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]-(+)-biphenyl-4-yl}cyclopropanecarboxylic acid;

(+)-(trans)-2-{3'-[3-{[(1-methylcyclopropyl)amino]carbonyl}-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid;

2,2-dimethyl-4-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}butanoic acid;

2,2-dimethyl-3-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}propanoic acid;

(-)-(trans)-2-{3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid; or

(+)-(trans)-2-{3'-[4-oxo-3-{[(2,2,2-trifluoroethyl)amino]carbonyl}-1,8-naphthyridin-1(4*H*)-yl]biphenyl-4-yl}cyclopropanecarboxylic acid.

22. A pharmaceutical composition comprising

a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

23. The pharmaceutical composition according to claim 22, further comprising a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, an M2/M3 antagonist, a corticosteroid, an H1 receptor antagonist or a beta 2 adrenoceptor agonist.

24. The pharmaceutical composition according to claim 22, further comprising a COX-2 selective inhibitor, a statin, or an NSAID.

25. A method of treatment or prevention of asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock (and associated conditions such as laminitis and colic in horses), septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, osteoporosis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease, hypersecretion of gastric acid, bacterial, fungal or viral induced sepsis or septic shock, inflammation and cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, monopolar depression, acute and chronic neurodegenerative disorders with inflammatory components, Parkinson disease, Alzheimer's disease, spinal cord trauma, head injury, multiple sclerosis, tumour growth and cancerous invasion of normal tissues comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

26. A method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of compound according to claim 1, or a parmaceutically salt thereof.

27. A method according to claim 25 wherein the amount of compound is insufficient to emisis in said subject.

28. A method according to claim 25 wherein the subject is a human of age 55 or older.

29. A compound according to claim 2 wherein Y is -C_{3-6}cycloalkyl(C_{1-4}alkyl)$_m$-COOH, wherein the C_{3-6}cycloalkyl is optionally substituted with halogen, alkoxy, hydroxy or nitrile, and the (C_{1-4}alkyl) substituents are optionally linked to form a C_{3-6}cycloalkyl; wherein n is 0, 1, 2, 3 or 4, m is 0, 1.